Get the Immuno-oncology eBook

Many cancer patients fail to respond to treatment or even develop harmful immune-related adverse events (irAEs). This has led not only to the FDA halting clinical trials in some cases, but also to clinicians running the risk of triggering these effects in patients undergoing immunotherapy.

In this eBook, you will:

  • Discover what is holding back the development of effective and safe cancer immunotherapies today
  • Learn about why taking a biomarker-driven approach to immunotherapy development will help inform more effective drug development and treatment strategies.
  • Discover how new research is indicating strongly that autoantibodies may be the robust biomarker of choice for cancer immunotherapy

Simply fill out your details below to receive your download.

We sometimes like to share the latest industry insights and company news, would you like to be added to our database?

13 + 10 =

Copyright © 1997-2018
Protagen AGDortmund, Germany